Clinical Digest: Recent Clinical Trials on Genital Herpes
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Genital Herpes. These trials are organized by their release dates for your convenience. (Last updated on: 2025-05-02)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Genital Herpes
| Clinical Trial | Contact(s) | Date | |
|---|---|---|---|
| 1 | Phase II Clinical Trial of HSV G207 with A Single 5 Gy Radiation Dose in Children with Recurrent High-Grade Glioma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric high-grade gliomas |
GREGORY FRIEDMAN; | 2025-04-01 |
| 2 | Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Acute liver failure (ALF) is a serious condition in which the liver suddenly stops working, often leading to life-threatening complications. While N-Acetylcysteine (NAC) is widely used to treat ALF caused by acetaminophen overdose, its benefits in ALF due to other causes, such as viral infections or drug reactions, remain uncertain. This study is a randomized controlled trial designed to investigate whether NAC can improve survival rates and reduce hospital stays in patients with non-acetaminophen-induced ALF. Participants will be randomly assigned to receive either NAC along with standard supportive care or standard supportive care alone. The study will measure survival rates, … |
MUHAMMAD IRFAN JAMIL; | 2025-01-15 |
| 3 | A Phase 2 Study of Intralesional RP2 As Immunoprevention for High-Risk Oral Precancerous Disease (INTERCEPT) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain) |
GLENN J. HANNA; | 2025-01-01 |
| 4 | A Phase 1a/1b, Blinded, Placebo-Controlled Study of The Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A. |
ASSEMBLY BIOSCIENCES | 2024-12-08 |
| 5 | A Phase 1a/1b, Blinded, Placebo-Controlled Study of The Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 with Recurrent Genital Herpes PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A. |
ASSEMBLY BIOSCIENCES | 2024-05-30 |
| 6 | Phase 1 Study of Intratumoral Administration of JNJ-87704916, An Oncolytic Virus, As Monotherapy and in Combination for Advanced Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab. |
JOHNSON & JOHNSON ENTERPRISE INNOVATION | 2024-04-10 |
| 7 | Phase I Pilot Study of RP1 in Primary Melanoma to Reduce The Risk of Sentinel Lymph Node Metastasis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells and does not infect healthy cells. This results in tumor cell lysis and the release of virus particles which infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune system is activated by the released tumor-associated antigens (TAAs) from the tumor cells creating an anti-tumor immune response against the tumor cells, … |
YANA NAJJAR; | 2024-03-07 |
| 8 | Effect of Acyclovir Therapy on The Outcome of Ventilated Patients With Lower Respiratory Tract Infection and Detection of Herpes Simplex Virus in Bronchoalveolar Lavage PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can’t get rid of them for the rest of her/his life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, … |
STEFAN HAGEL; | 2024-02-20 |
| 9 | A Phase I Adaptive, Multiple Dose Pharmacokinetic and Safety Assessment of Valacyclovir in Infants at Risk of Acquiring Neonatal Herpes Simplex Virus Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2023-08-07 |
| 10 | A Case-Control Study on The Association Between Periodontal Health and Gingival Crevicular Level of Matrix Metalloproteinase-8 in Post COVID-19 Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is; To Assess the association between periodontal health and Matrix metalloproteinase-8 (MMP-8) level in Gingival Crevicular Fluid (GCF) in post COVID-19 patients. |
RANDA NIDAL ALZOUBI; | 2023-08-01 |
| 11 | Investigation of The Passage of Antiviral Antibodies From Mother to Child PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Infections remain a major cause of neonatal morbidity and mortality worldwide. At birth, multiple microorganisms, to which they are particularly vulnerable given the immaturity and naïve nature of their immune system, … |
CHRISTELLE VAULOUP FELLOUS; | 2023-05-15 |
| 12 | A Single-blinded Sham-controlled Crossover Trial to Evaluate The Effect of Immunoadsorption on Post-Corona Virus Disease (COVID)-Syndrome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to evaluate the efficiency and safety of immunoadsorption for the treatment of post-COVID syndrome (PCS). Efficacy will be measured (1) subjectively as an improvement of the score of questionnaires like the multidimensional fatigue inventory (MFI-20), Chalder fatigue scale, Bell-score, … |
JULIA WEINMANN-MENKE; | 2023-05-08 |
| 13 | Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2 Related Papers Related Patents Related Grants Related Experts View Highlight: AiCuris Anti-infective Cures AG (AiCuris) is developing pritelivir for the oral treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infections in immunocompromised subjects. The purpose of the expanded access program (EAP) is to provide pritelivir to immunocompromised subjects with treatment resistant HSV type 1 or 2 who cannot participate in a clinical trial and for whom no approved treatment option is available. In view of the available pre-clinical and clinical data for pritelivir in immunocompromised subjects with treatment resistant HSV, the lack of treatment options, and the demand for compassionate use of pritelivir, … |
AICURIS ANTI INFECTIVE CURES AG | 2023-04-25 |
| 14 | Assessment Of Gene Expression Of Suppressor Of Cytokine 3, Interferons Alpha And Beta In Cutaneous Warts PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Warts are common epidermal growths caused by various strains of human papilloma virus (HPV). Viral warts are common with a prevalence rate of 7-12%. Human papilloma virus is small non enveloped viruses that contain a double-stranded DNA genome. There are more than 200 HPV genotypes are reported, however, the high-risk types, including HPV genotype-16 (HPV16), 18, 31, and 45, are the causes of 80% of cervical cancers. |
REHAM HELAL ABOELHAMD; | 2023-04-15 |
| 15 | NOWDx Test for The Diagnosis of Herpes Simplex Virus Type 2 PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is designed to compare the performance of the NOWDx HSV-2 Test to a currently marketed device. The intent is to show the rapid test device is comparable to the currently marketed device. The NOWDx HSV-2 Test is intended for qualitatively detecting the presence or absence of human Immunoglobulin G (IgG) class antibodies to HSV-2 in human whole blood to aid in the diagnosis of infection caused by herpes simplex virus type 2 (HSV-2). |
BETH COBB; | 2023-03-01 |
| 16 | Extraordinarily Fun Training Project in Compulsory Secondary Education-Sexually Transmitted Infections: Educational Intervention on STI in Adolescents From 1st&2nd Year of Compulsory Secondary Education Incorporating The Gender Perspective PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Project FEDE-ITS will improve the STI knowledge and its treatment, of adolescents in the 1st and 2nd year of compulsory secondary education in the intervention group compared to compared to the control group, and will modify the sexual risk practices and the perception of risky practices of alcohol and other drug use during sex of participants in the intervention group compared to the control group. |
DAVID PEDRAZAS-LÓPEZ; | 2023-03-01 |
| 17 | Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The number of obese people will reach 50% of the world population by 2035. Obesity is a chronic disease. For obese patients, dosage regimens have been determined for patients with a normal BMI between 20-30 kg/m2. Based on plasma and urine concentrations, a pharmacokinetic model will be performed to study in healthy volunteers, the predictive character of lean mass, measured by DEXA, on renal elimination and therefore on acyclovir exposure. The main objective of this study is to evaluate, in 4 volunteers groups representative of (1) non-obese (18-24.9 kg/m2), (2) overweight (25-29.9 kg/m2), … |
SARAH BAKLOUTI; | 2023-03-01 |
| 18 | Integrating Addiction and Infectious Diseases Services Into Primary Care in Rural Settings PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia. The main questions it aims to answer are: * What are the barriers and facilitators to integrating evidence based practices for screening and treatment of HIV, hepatitis C, and Opioid Use Disorder into primary care clinics in West Virginia? * To assess the extent to which our SET processes are achieved through enhanced EHR tools, … |
FREDERICK L ALTICE; | 2023-01-24 |
| 19 | Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate The Safety, Tolerability, and Immunogenicity of An Investigational Prophylactic Vaccine for The Prevention of Genital Lesions Caused By Herpes Simplex Virus (HSV)-2 and Potentially HSV-1 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety evaluations, and in addition, … |
BIONTECH SE | 2022-12-08 |
| 20 | Knowledge of Young Adults About Genital Herpes PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection. |
UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE | 2022-12-02 |
| 21 | Association Between Periodontitis and Coronavirus Disease (COVID-19) On A Sample of Adult Egyptian Patients: A Case Control Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study is a case control study investigating the association between Periodontitis and Coronavirus disease (COVID-19) in Egyptian dental patients attending the oral diagnosis clinic at faculty of Dentistry, Cairo University. |
OMAR KHALED GAMIL MOUSSA MEGAHED; | 2022-08-15 |
| 22 | A Study of The Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Determine the baseline characteristics of patients who have recurrent symptomatic genital herpetic disease Determine the acceptance to patients of clinical trial procedures Determine interest in participation in genital herpes vaccine trials |
RAJUL PATEL; | 2022-08-03 |
| 23 | A Savings Intervention to Reduce Men’s Engagement in HIV Risk Behaviors PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This randomized control trial will test an economic intervention to reduce Kenyan men’s engagement in behaviors that increase the risk of HIV/STIs. Participants randomized to the intervention group will be able to open accounts with a partner bank and will be incentivized to save with lottery-based rewards. |
HARSHA THIRUMURTHY; | 2022-07-18 |
| 24 | A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment. |
HUI QIU; | 2022-07-01 |
| 25 | Optimal Dosing and Timing of Corticosteroids in Hospitalized Patients With COVID-19 PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Rationale: In patients with COVID-19 admitted to the hospital, large heterogeneity exists in patients, timing and dosing of steroid therapy. It is unclear how to treat patients who fail dexamethasone therapy. High-dose steroids are prescribed mainly in patients with the most severe disease, which may be too late given the potential escalation of pathophysiological pathways in these patients. Objectives: The main objective is to determine the most optimal form, … |
HENRIK ENDEMAN; | 2022-06-01 |
| 26 | Herpes Simplex Virus-1: A Pilot Study Using Hand Sanitizer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion. The duration of an HSV-1 (herpes) lesion is the primary endpoint for this study. Size, pain, and discomfort are the secondary endpoints. |
LECIEL BONO; | 2022-04-08 |
| 27 | A Phase I/II, Observer-blind, Randomised, Placebo-controlled, Multi-country Study to Evaluate Reactogenicity, Safety, Immune Response, and Efficacy of An HSV Vaccine in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent HSV-2 Genital Herpes PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV) vaccine. The study will be conducted in 2 parts: Part I assessing different formulations of the vaccine candidate in healthy participants aged 18-40 years; Part II assessing the selected formulation of the vaccine candidate in participants aged 18-60 years with recurrent herpes simplex virus type 2 (HSV-2) genital herpes. |
ISABEL LEROUX-ROELS; | 2022-03-07 |
| 28 | A Randomized, Efficacy Assessor-Blinded, Study to Assess Preliminary Efficacy and Safety of EDTA Eye Drops V. An Active Comparator in The Suppression of Herpes Simplex Virus Eruptions in Subjects With A History of Herpes Labialis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 20 subjects with documented herpes labialis. Patients will be treated with the study drug, EDTA Eye Drops or the active comparator of Abreva. Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, … |
CHRISTOPHER HULL; | 2022-01-20 |
| 29 | Host RNA Expression Profiles and Protein Biomarkers in Neonatal Herpes Simplex Virus Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study seeks to identify and test host RNA expression profiles in context to protein biomarkers in dried blood spot samples as novel diagnostic markers of neonatal herpes simplex virus infection and to improve the understanding of the pathogenesis of the disease. |
KIA HEE SCHULTZ DUNGU; | 2022-01-01 |
| 30 | A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of The PREVENT-COVID-19Program PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60 years of age. |
KENNETH PALMER; | 2021-11-11 |
| 31 | Safety and Efficacy Study of Oncolytic Virus（Intratumoral Injection）in Combination With HX-008（Intravenous Injection）and Axitinib in Melanoma Patients With Liver Metastasis Who Lack or Become Refractory to Standard Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts. Melanoma is one of the fastest growing malignant tumors with an annual incidence rate of 3-5%. In 2012, there were 232000 new cases of melanoma and 55000 deaths worldwide. Though, the incidence rate of melanoma is relatively low in China, it has been increasing rapidly in recent years. Melanoma has seriously endangering the health of Chinese people. Patients with stage Ⅳ melanoma have a poor prognosis. According to statistics, … |
JUN GUO; | 2021-10-01 |
| 32 | Safety and Efficacy Study of Oncolytic Virus（Intratumoral Injection）in Combination With HX-008（Intravenous Injection）and Radiotherapy for Liver Metastasis in Melanoma Patients With Liver Metastasis Who Lack or Become Refractory to Standard Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Malignant melanoma, is a kind of malignant tumor derived from melanocytes. It is common in skin, mucous membrane, eye choroid and other parts. Melanoma is one of the fastest growing malignant tumors with an annual incidence rate of 3-5%. In 2012, there were 232000 new cases of melanoma and 55000 deaths worldwide. Though, the incidence rate of melanoma is relatively low in China, it has been increasing rapidly in recent years. Melanoma has seriously endangering the health of Chinese people. Patients with stage Ⅳ melanoma have a poor prognosis. According to statistics, … |
JUN GUO; | 2021-10-01 |
| 33 | Pharmacokinetics of Intravenous Acyclovir in Children Undergoing Hematopoietic Stem Cell Transplantation or High-intensity Antineoplastic Chemotherapy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: – Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality. – Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving high-intensity chemotherapy for hematological malignancies are the most vulnerable individuals. – Although the worldwide prevalence of herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV), antiviral prophylaxis in seropositive HSCT recipients has significantly reduced the rate of infection. – Acyclovir (ACV) is the first-choice drug for the prophylaxis or the therapy of that kind of infection. – Since the beginning, ACV has demonstrated to be characterized by a large interpatient variability, … |
ANTONELLO DI PAOLO; | 2021-09-15 |
| 34 | A Pilot Study Assessing The Feasibility of Using Clitoral Vibrators to Aid Vaginal Dilator Therapy in Women Presenting to Psychosexual Services With Vaginismus PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The acceptability of vulvar vibration therapy has been evaluated in women with vulvodynia, and found to be acceptable, however has not been assessed in women with a primary complaint of vaginismus. This proposed study looks at the feasibility and acceptability of using clitoral vibration therapy, alongside current therapy, for women with vaginismus. It is likely that many, if not most, of these women will also have an element of vulvodynia. The investigators propose that the use of external clitoral or vulval vibration therapy is likely to be acceptable in most women with vaginismus, … |
JESS GADDIE; | 2021-08-11 |
| 35 | Evaluation of The Pharmacokinetics and Pharmacodynamics of Valacyclovir in Neonates with Neonatal Herpes Simplex Virus Disease Who Have Completed Standard of Care Treatment with Acyclovir Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label, single center, pharmacokinetic (PK) study to assess valacyclovir pharmacokinetics and pharmacodynamics in neonates and compare to the pharmacokinetics and pharmacodynamics of the standard of care treatment dose of intravenous acyclovir. 6 (up to 10 infants) with virologically confirmed neonatal herpes simplex virus (HSV) disease who meet all inclusion/exclusion criteria will be enrolled in the study. Study duration is 5 years. Primary objective is to define the pharmacokinetics of valacyclovir and assess its safety in neonates 2-12 weeks of age who are ≥ 34 weeks gestation. |
RICHARD J WHITLEY; | 2021-07-01 |
| 36 | Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The DepIST-H study, funded by the French AIDS and Hepatitis Research Agency (ANRS), is to estimate prevalence (the number of cases over a given period of time) and incidence (the number of new cases over a given period of time) of anal lesions (condylomas, dysplasia, cancers) by HIV status among MSM in Lomé, Togo |
CHARLOTTE CHARPENTIER; | 2021-06-24 |
| 37 | A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in The United States and Europe PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe. More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well as the performance study procedures in a decentralised setting. Ultimately, this study will allow generating additional real-world evidence (RWE) on patterns of recurrences and other key parameters. |
GLAXOSMITHKLINE | 2021-06-09 |
| 38 | The Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection |
ALSHAIMAA AHMED SHABAAN; | 2021-05-20 |
| 39 | Depression, Meth Use, and Safe Sex Behaviors: Assessing The Feasibility and Acceptability of An HIV Cognitive Behavioral Intervention for Young Adult Latina Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The study uses a repeated measures, single group pretest-posttest design methodology to examine the feasibility, acceptability, and preliminary effectiveness of the FASTLANE II intervention aimed at decreasing risky sex behaviors among active methamphetamine using women. The study’s methodology consists of two phases: 1) The feasibility and evaluation of recruitment capability and intervention effectiveness, and 2) qualitative acceptability interviews. |
ALICE CEPEDA; | 2021-05-03 |
| 40 | Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19: Pragmatic, Web-based Bayesian Adaptive Randomised Controlled Trial in Pakistan PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Nasal washing (washout) followed by gargles with hypertonic saline (HSNIG) is believed to be effective in reducing the duration of illness in those with clinically suspected or confirmed COVID-19 being managed at home, and also is effective in reducing complications of COVID-19 and onward household transmission. This study plans to investigate whether the use of HSNIG performed by adults with symptoms consistent with COVID-19 reduces the duration of symptoms when compared to participants managed using standard care. |
OSMAN YUSUF; | 2021-05-01 |
| 41 | Phase Ib/II Study of OH2 Injection, An Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Pancreatic Cancer PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase Ib/II study evaluates the safety and efficacy of OH2 in patients with locally advanced/metastatic pancreatic cancer who have failed first-line standard treatment. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response. |
BINHUI BIOPHARMACEUTICAL | 2021-02-02 |
| 42 | Anti Viral Treatment in Mild Cognitive Impairment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI) patients (eMCI and lMCI). The trial will directly address the long-standing viral etiology hypothesis of Alzheimer’s disease (AD) which posits that viruses, particularly the very common herpes simplex virus-1 (HSV1) and herpes simplex virus-2 (HSV2), … |
DAVANGERE P. DEVANAND; | 2021-02-01 |
| 43 | Randomized, Placebo-controlled, Double-blind Study to Evaluate The Efficacy of 2LHERP® in Patients With Recurrent Genital Herpes Infections PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Herpes simplex virus (HSV) infection is very common, as most people will experience herpetic infection during their lifetime. The most common manifestation of HSV infection is sores which may appear at any age. No specific antiviral therapy is available to totally cure herpetic infections and today, there is no treatment that allows the definitive eradication of the virus. The 2LHERP® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of herpetic infections. Since 2LHERP® has been made available, … |
STÉPHANIE BLONDEL; | 2021-01-25 |
| 44 | Study to Investigate The Benefits of Dietary Supplement Quercetin for Early Symptoms of COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables. It has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties. It is widely used to boost the body immune system against infections and keeping healthy life-style. The purpose of the present study is to investigate the potential benefits of quercetin for preventing COVID-19 disease progression and symptoms improvement in the early stage of infection. |
KING EDWARD MEDICAL UNIVERSITY | 2021-01-11 |
| 45 | Efficacy and Safety of Ovotransferrin in COVID-19 Patients With Mild-to-Moderate Disease PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Chicken egg consists of three main components, egg white (56%), yolk (33%) and shell (11%). The key component of egg white is 88 percent water and 12 percent solids, of which over 90 percent are protein. Ovalbumin, ovotransferrin, and ovomucoid are considered the main proteins, while ovomucin, lysozyme, ovoglobulin, ovomacroglobulin, ovoglycoprotein, ovoflavoprotein, thiamin-binding proteins, ficin/papain inhibitors, avidin, and cystatin are the minor white proteins of the embryo. These proteins and their peptides have been recognized as antioxidants, antimicrobials, metal-chelators, anti-viral, anti-tumor, and angiotensin-converting enzyme (ACE)-inhibitors for their functional significance SARS-CoV-2 virus activates the human cell ACE2 receptor, … |
ANTONIO CASCIO; | 2020-12-01 |
| 46 | Phase Ib Study of The Combination Use of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) and HX008 Injection in The Treatment of Melanoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response. |
BINHUI BIOPHARMACEUTICAL | 2020-12-01 |
| 47 | Effects of Kabat Technique and Neuromuscular Re-Education in Patients With Bell’s Palsy PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Bell’s palsy is the sudden one-sided peripheral weakness of seventh cranial nerve (Facial nerve), represents 50% to 75% of all etiologies with a rate of 58.2 to 8 new cases per 1 million per year. The objective is to compare the effects of Kabat techniques and Neuromuscular Re-Education on facial disability and synkinesis in patients with bell’s palsy. A Randomized Control Trial was conducted on 20 participants, equally allocated in Kabat and PNF training group from February-2020 until December- … |
ARUBA SAEED; | 2020-11-15 |
| 48 | CRISPR/Cas9 MRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in The Treatment of Refractory Viral Keratitis Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered via corneal injection in participants with refractory herpetic viral keratitis. |
YUJIA CAI; | 2020-11-04 |
| 49 | A Phase 1/2 Study of AgenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 or Influenza PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A Phase 1/2 study of agenT-797 to treat moderate to severe acute respiratory distress syndrome (ARDS) secondary to acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or influenza. |
MINK THERAPEUTICS | 2020-09-21 |
| 50 | An Open Label, Randomized Controlled Clinical Study on The Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in The Treatment of Malignant Pleural and Peritoneal Effusion PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Theory of VAK： 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects. 2. Releasing of tumor-associated antigen could induce specific anti-tumor immune response. Preparation of VAK： 1. Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal Effusion. 2. Incubate the immune cells with inactivated viruses and tumor cells. 3. Wash to remove impurities. 4. Intrapleural the immune cells to patients |
SHENG HU; | 2020-07-24 |
| 51 | Esophageal Mucosal Changes in Long Standing Achalasia Cardia and Reversibility After Per Oral Endoscopic Myotomy ( POEM ) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Esophageal mucosal changes in long standing achalasia cardia and reversibility after per oral endoscopic myotomy – A pilot study Aims and Objectives: – To study mucosal changes in patients with achalasia cardia – To study potential malignant histopathological findings in long standing achalasia cardia – To assess reversibility of mucosal changes after POEM – To study co-relation of mucosal histopathology with predictors of sub-mucosal fibrosis – To study muscle biopsy by light microscopy and electron microscopy for viral inclusions Materials and Methods: – Study Area – Patients of achalasia cardia undergoing POEM in Asian Institute of Gastroenterology. – … |
MOHAN RAMCHANDANI; | 2020-06-30 |
| 52 | Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Placebo-controlled Randomized Multicenter Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is the first and largest randomized, controlled, blinded trial that evaluates the efficacy of autologous cord blood mononuclear cells infusion as a prevention therapy for BPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of BPD in extremely preterm infants. In this prospective, randomized controlled double-blind multi-center clinical trial, … |
YANG JIE; | 2020-06-20 |
| 53 | Impact of COVID-19 Infection During Pregnancy on Maternal and Fetal Outcome PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To asses impact of the COVID-19 infection during Pregnancy on maternal and fetal outcome in relation to gestational age. |
MOHAMED ELSIBAI ANTER; | 2020-05-01 |
| 54 | The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has been discovered recently in December 2019 from wuhan city in China to spread in more than 40 countries allover the world. This disease has gain the attention of all nations after it has been stated as a pandemic by the World Health Organization (WHO) in March 12, … |
MAHMOUD AHMED TANTAWY; | 2020-04-15 |
| 55 | Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: acute viral encephalitis is used to describe restricted CNS involvement (namely, involvement of the brain, sparing the meninges) |
AA NAGY; | 2020-03-30 |
| 56 | Reducing Health Care Workers Absenteeism in COVID-19 Pandemic By Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, A Randomized Controlled Trial PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: Rationale: Covid-19 spreads rapidly throughout the world. A large epidemic in the Netherlands would seriously challenge the available hospital capacity, and this would be augmented by absenteeism of healthcare workers (HCW). Strategies to prevent absenteeism of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, … |
MJM BONTEN; | 2020-03-25 |
| 57 | Incidence, Risk Factors and Prognosis of Pulmonary Fibrosis During Severe COVID-19 Pneumonia PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), an emerging coronavirus, which has already infected 192 million people with a case fatality rate close to 2%. About 5% of patients infected with SARS CoV-2 have a critical form with organ failure. Among critical patients admitted to intensive care, … |
HÔPITAL EUROPÉEN MARSEILLE | 2020-03-11 |
| 58 | Genotype-Informed Versus Empiric Management of VirEmia (GIVE MOVE) in HIV-Infected Children and Adolescents on Antiretroviral Therapy: An Open-Label Randomised Clinical Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: HIV infection can be effectively controlled with antiretroviral therapy (ART). However, children and adolescents living with HIV and receiving ART suffer high rates of treatment failure, predominantly caused by suboptimal adherence to therapy and/or viral drug resistance. While high-income countries routinely use genotypic resistance testing (GRT) to determine which drug combinations are likely to be effective, this diagnostic tool is relatively costly and labour-intensive and is not routinely available in most resource-limited settings. GIVE MOVE is a multi-country (Lesotho, … |
JENNIFER A BROWN; | 2020-03-03 |
| 59 | Role of Influenza A VIRus in The Biomolecular Pathogenesis of The Destabilization of Atherosclerotic Carotid Plaques PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries, forming so-called plaques. The underlying molecular mechanisms are not yet clearly understood. In particular, it is not yet clear what factors can cause the destabilization of atherosclerotic plaques, … |
DANIELA MAZZACCARO; | 2020-02-18 |
| 60 | Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered By Intramuscular Route in Adults With Recurrent Genital Herpes Caused By HSV 2 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objectives of the study are: – To describe the safety profile of different investigational vaccine regimens against herpes simplex virus type 2 (HSV-2). – To evaluate the efficacy of the investigational vaccine regimens with respect to: – the frequency of herpes simplex virus (HSV) deoxyribonucleic acid (DNA) detection in the genital area (shedding rate) following a 2 dose vaccine schedule – the proportion of participants free of HSV genital recurrence at 6 months after the 2-dose vaccine schedule The secondary objectives of the study are: – … |
SANOFI PASTEUR A SANOFI COMPANY | 2020-02-18 |
| 61 | A Phase 1 Dose-escalation Study Testing The Feasibility and The Tolerance of Infusion of A Specific Third Party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T Cell Clone in HLA-DPB1*04:01 Positive Tumor Recipients Receiving An Allotransplant from A HLA-DPB1*04:01 Negative Donor Related Papers Related Patents Related Grants Related Experts View Highlight: For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies. The acceptance of umbilical cord blood (UCBT) and haploidentical grafts (Haplo) as viable alternative donors for allo-HSCT has increased the options for patients with no matched donors and now ensures that a donor can be identified for virtually all patients. Relapsed disease is a principal threat to these patients and affects 30-50% of them. The therapeutic options for these relapsing patients are diverse but remain largely ineffective in altering their long-term outcomes. Therefore, … |
NANTES UNIVERSITY HOSPITAL | 2020-02-09 |
| 62 | Investigate The Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Responses in The Eczema Herpeticum Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study investigates whether blood monocytes’ surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum. |
LIANGHUA BIN; | 2020-01-09 |
| 63 | Treatment of Herpes Labialis By Photodynamic Therapy: Controlled, Prospective, Randomized, Double-blind Protocol Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Lesions of herpes labialis are caused by the herpes simplex virus type 1 (HSV-1) and cause pain and aesthetic compromise. It is characterized by the formation of small vesicles that coalesce and rupture forming extremely painful ulcers, that evolve to crusts, dry desquamations until their complete remission. Currently, the treatment of these lesions is done with acyclovir. Although it diminishes the symptomatology, it causes viral resistance and does not prevent the recurrence of the lesions. It is known that photodynamic therapy (PDT) has numerous advantages, among them: the reduction of the time of remission, … |
ANNA CAROLINA RATTO TEMPESTINI HORLIANA; | 2020-01-01 |
| 64 | Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 As A Complementary Medicine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Boswellia Serrata gum and Licorice extract are two nutritional agents that have pharmacological actions that could support the medical intervention for COVID-19. They have broad antiviral activity, anti-inflammatory, anti-lung injury, antibacterial activity, antithrombic formation, and immunomodulatory activity. The study will be conducted after January 18, 2017 |
ADEL GOMAA; | 2020-01-01 |
| 65 | A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective, randomized clinical trial looking to determine the role of prophylactic treatment with topical corticosteroids in preventing recurrences in patients with a history of infectious epithelial keratitis, stromal keratitis,endotheliitis, or iridocyclitis. Patients will be enrolled to one of two treatment arms: Control arm: oral acyclovir 400 mg BID OR valacyclovir 500 mg daily or Study arm: oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops. |
NYU LANGONE HEALTH | 2019-12-10 |
| 66 | Pharmacokinetics of A New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections in Children, Phase II (VALID II) Related Papers Related Patents Related Grants Related Experts View Highlight: Valacyclovir has replaced acyclovir in many clinical scenarios. Pharmacokinetic data support the use of oral valacyclovir in children, but practical problems exist in children having to take adult-dose tablets. A formulation with acceptable palatability, good pharmaceutical quality and possibility of flexible dosing is developed. Pharmacokinetic data of this formulation is missing. The present study investigates the pharmacokinetics of valacyclovir oral solution in children by determine the area under the curve (AUC0-12), time above critical concentration (Ccrit), Cmax and Tmax of acyclovir. Secondary, the safety profile of a single dose of valacyclovir oral solution will be determined. |
RADBOUD UNIVERSITY MEDICAL CENTER | 2019-12-10 |
| 67 | A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 Versus Standard of Care Valaciclovir in Patients With Chronic Recurrent Anogenital HSV-2 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a randomized, double-blind, double-dummy study of single dose HDIT101 versus Standard of Care Valaciclovir. HSV-2-positive patients with at least 4 anogenital herpes lesions in the last 12 months (or at least 2 herpes lesions with previous valaciclovir long-term therapy) can be included. If a patients develops a anogenital Herpes lesion within 4 months after the screening visit, … |
HEIDELBERG IMMUNOTHERAPEUTICS | 2019-11-15 |
| 68 | Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD |
GREGORY FRIEDMAN; | 2019-09-12 |
| 69 | A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse. |
RHONDA BRAND; | 2019-07-10 |
| 70 | Phase I/II Study of OH2 Injection, An Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft tissue sarcomas). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response. |
BINHUI BIOPHARMACEUTICAL | 2019-04-02 |
| 71 | Repeating A Lumbar Puncture at 24 Hours Versus 48 Hours After A Macro-traumatic Lumbar Puncture in Newborn Infants: A Randomized Controlled Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Visibly traumatic as well as microtraumatic lumbar punctures (LP) are very common in the neonatal period. The presence of blood makes it difficult to interpret cerebro-spinal fluid (CSF) findings. Clinicians often perform a repeat LP in the hope that some of the red blood cells would have cleared by then, allowing a better interpretation of the CSF findings. There is no published information whether a repeat LP provides any added information to the original traumatic LP, and if so what is the best time to repeat an LP after a traumatic LP. In this randomised controlled trial (RCT), … |
SOURABH DUTTA; | 2019-03-18 |
| 72 | Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Related Papers Related Patents Related Grants Related Experts View Highlight: Bacterial meningitis occurs in about 3 people per 100,000 annually in Western countries. . |
DOHA FAHMY; | 2019-01-01 |
| 73 | Shamba Maisha: Assessing The Preliminary Effects of A Multisectoral Agricultural Intervention on The Sexual and Reproductive Health of HIV-affected Adolescent Girls in Western Kenya PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The goal of this study is to understand how the Shamba Maisha household agricultural and economic intervention impacts the sexual, reproductive, and nutritional health of adolescent girls. The intervention includes: a) a human-powered water pump and other required farm commodities, b) a micro-finance loan (~$75) to purchase the pump and agricultural implements, and c) education in sustainable farming practices. |
SHERI D WEISER; | 2018-12-05 |
| 74 | Open and Incremental Phase I Clinical Trial of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) in The Treatment of Advanced Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response. |
BINHUI BIOPHARMACEUTICAL | 2018-11-22 |
| 75 | Dexamethasone in Herpes Simplex Virus Encephalitis Open Label Randomized Controlled Trial With An Observer-blinded Evaluation at 6 Months PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Encephalitics is a serious condition in which the brain becomes inflamed (swollen). It usually happens as a direct result of virus, such as herpes simplex virus (HSV). HSV encephalitis is often treated with the drug acyclovir (an antiviral drug which slows the growth and spread of HSV in the body). Despite this however, around 2 out of every 3 people will have memory difficulties long term. Dexamethasone is a corticosteroid medication, … |
JEAN-PAUL STAHL; | 2018-11-01 |
| 76 | Evaluation of The ShangRing Vs. Mogen Clamp for Early Infant Male Circumcision (EIMC) in Sub-Saharan Africa PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The study will evaluate the safety and acceptability of the topical anesthesia-based, no-flip ShangRing technique vs. Mogen clamp for Early Infant Male Circumcision (EIMC) in neonates and infants up to 60 days of life. The study will consist of 2 phases; a pilot phase and a field study. In the pilot phase, male infants of up to 60 days of life will be enrolled in three sub-Saharan countries, specifically Kenya, Tanzania, … |
RICHARD K LEE; | 2018-10-01 |
| 77 | Phase I Clinical Trial on Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Over the past few years it has become evident that cancer cells can be recognized by the patient’s own immune system. The immunological mechanisms at play are often referred to as the cancer immune cycle (Chen and Mellman 2013; Mellman 2013; Chen and Mellman 2017).In immune-evasive tumors a pivotal role has been attributed to myeloid dendritic cells (myDC) in regulating the activity of anti-tumor CTL activity within the TME (Broz, Binnewies et al. 2014). In animal models, … |
BART NEYNS; | 2018-09-28 |
| 78 | Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Herpes virus can cause sores on the body. It can cause flu-like symptoms like fever and muscle aches, and even a type of cancer. Many people with HIV also have infections with herpes virus. When these people start taking HIV medicines, … |
STEVEN J REYNOLDS; | 2018-06-15 |
| 79 | Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: Objective: To evaluate the effectiveness of a combined strategy of human papillomavirus virus (HPV) vaccination and high-risk HPV screening to reduce the occurrence of neoplasms in the anogenital region and oral cavity among men who have sex with men, people with HIV, homeless people, transgender women, female sex workers and rape victims. Methods: This mixed methods study evaluates the effectiveness of a combined vaccination-screening strategy to reduce HPV prevalence/incidence and occurrence of cervical intraepithelial neoplasms grade 2+ and/or anal intraepithelial neoplasms grade 2+, … |
EDUARDO CESAR LAZCANO PONCE; | 2018-05-30 |
| 80 | A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Primary Objective: To assess local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months). Secondary Objective: To assess efficacy of repeat topical application of 2% and 0.5% SADBE in the prevention of herpes labialis episodes. |
SQUAREX | 2018-03-12 |
| 81 | Anti-viral Therapy in Alzheimer’s Disease PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Anti-viral therapy in Alzheimer’s disease will investigate the efficacy of treating patients with mild Alzheimer’s disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alzheimer’s disease, will be compared to matching placebo in the treatment of 130 mild AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month Phase II proof of concept trial. |
DEVANGERE P. DEVANAND; | 2018-02-12 |
| 82 | Application of Next Generation Sequencing Technique in Pediatric Bacterial Meningitis PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Pathogen identification is of paramount importance for bacterial meningitis. At present, the pathogen of bacterial meningitis is still mainly based on Gram stain and bacterial culture. However, cerebrospinal fluid (CSF) culture can be negative in children who receive antibiotic treatment prior to CSF examination.Because of the limitations of clinical laboratory testing, … |
GANG LIU; | 2018-02-01 |
| 83 | Clinical and Immunological Study of The Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection) By Acyclic Nucleoside Valacyclovir and Interferon Inducer Kagocel PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by acyclic nucleoside Valacyclovir and antiviral agent Kagocel versus monotherapy by Valacyclovir. This study also evaluated the structure of herpesvirus infections and the rate of mixed variants of the course, the rate of exacerbations of herpes simplex, the time of disappearance of human herpesvirus isolation and the features of the immune phenotype of patients taking different types of therapy. |
GEORGY VIKULOV; | 2017-10-30 |
| 84 | Oral and Perioral Herpes Simplex Virus Infection Type I in A Five-month-old Infant: A Case Report Related Papers Related Patents Related Grants Related Experts View Highlight: A five-month-old healthy girl who presented with painful herpetic gingivostomatitis and perioral vesicles. |
ASHWAG YAGOUB ALOYOUNY; | 2017-10-19 |
| 85 | Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment. |
NYU LANGONE HEALTH | 2017-08-23 |
| 86 | The Association Between Herpes Simplex Viruses (Type One and Two) and Autism Spectrum Disorders PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Autism spectrum disorders are pervasive developmental disorders that include autistic disorder, Asperger’s disorder, and pervasive developmental disorder-not otherwise specified.They are characterized by stereotypic behaviors, variable deficits in language and social skills and a wide range of other behavioral problems. Autism spectrum disorders manifest during childhood and at least thirty percent present with sudden clinical regression of development around three years of age. |
KHALAF A SAYED; | 2017-08-01 |
| 87 | Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed By Pembrolizumab PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple negative breast cancer (TNBC) and metastatic non-small cell lung cancer (NSCLC). In situ oncolytic virus therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus valacyclovir therapy. |
JENNY C. CHANG; | 2017-07-01 |
| 88 | A Randomized, Placebo-controlled, Double-blind Study to Assess The Efficacy and Safety of A Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003. |
GENOCEA BIOSCIENCES | 2017-05-24 |
| 89 | A Randomized, Open Label, Multi-center, Comparative Trial, to Assess The Efficacy and Safety of Pritelivir for The Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, … |
AICURIS ANTI INFECTIVE CURES AG | 2017-05-08 |
| 90 | Comparative Effectiveness of Treatment Options for Genital Herpes Infection in Pregnant Women to Reduce Adverse Pregnancy Outcomes PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: Preterm delivery (PTD), together with low birthweight (LBW), is the leading cause of infant death and illness, affecting 500,000 births with annual medical costs of more than $26 billion in the U.S. each year. Identifying changeable risk factors to reduce PTD is considered a top research priority. Recent research has shown genital herpes infection (HSV) is associated with increased risks of PTD and LBW. More importantly, treating this infection, including infection with no symptoms, using readily available antiviral medications can be effective in removing the risk due to HSV. Thus, … |
DE-KUN LI; | 2017-03-14 |
| 91 | A Pilot Study of Nelfinavir for The Treatment of Kaposi Sarcoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
SOREN GANTT; | 2017-03-13 |
| 92 | A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate The Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: There are 2 fold of purposes for this study. 1 is to evaluate safety and tolerability and the other is to study the anti-tumor effects of talimogene laherparepvec in Japanese participants with unresectable stage IIIB-IV malignant melanoma. |
AMGEN | 2017-03-07 |
| 93 | A Phase I Study of The Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Subjects were recruited who were positive for antibody against herpes simplex virus type 1 (HSV-1) and self-reported having in the previous 12 months – 6 or more herpes labialis outbreaks (group A), – 1 or 2 outbreaks (group B), or – zero outbreaks (group C). Twelve subjects in each group were recruited. Blood was collected from these persons and peripheral blood mononuclear cells (PBMCs) isolated and tested for proliferation in vitro when stimulated with HSV-1-infected cell extracts, free HSV-1 virus, … |
MARK MATSON; | 2017-03-02 |
| 94 | Phase 1 Safety and Pharmacokinetic Study of A Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This prospective, two-site, two-arm, randomized, single-blind, placebo-controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 84 consecutive days by sexually active women. The primary objective is to assess the safety of TDF vaginal rings when used continuously for 84 days by healthy, HIV-uninfected, sexually active women, as compared with a placebo vaginal ring. |
MARLA KELLER; | 2017-02-24 |
| 95 | Integrated Extreme Trait Analysis to Understand The Etiology of Eczema Herpeticum (ADRN-06) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Atopic dermatitis, also called eczema, is a disease with dry, scaly, itchy skin. Those with atopic dermatitis may have complications from skin infections such as eczema herpeticum after herpes simplex virus (HSV) infection. Symptoms of eczema herpeticum include fever and clusters of itchy blisters which crust over and form sores. Although exposure to HSV is widespread, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2017-02-22 |
| 96 | ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed By Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a Phase II trial to determine the efficacy and safety of in situ gene therapy and stereotactic body radiation therapy (SBRT) used as a window of opportunity treatment before nivolumab in patients with metastatic squamous or non-squamous non-small cell lung carcinoma (NSCLC) and metastatic uveal melanoma. In situ gene therapy will consist of adenovirus-mediated expression of herpes simplex virus thymidine kinase (ADV/HSV-tk) plus Valacyclovir therapy. |
ERIC BERNICKER; | 2017-02-15 |
| 97 | A Randomized Controlled Trial Evaluating Efficacy of Promoting Voluntary Medical Male Circumcision Among Male Sexually Transmitted Diseases Patients in China PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: A parallel-group, non-blinded randomized controlled trial was conducted. Participants were uncircumcised heterosexual male sexually transmitted disease patients attending the four collaborative public sexually transmitted diseases clinics in three Chinese cities. Those who were known to be HIV positive were excluded. After completion the baseline face-to-face interview, 238 participants will be randomized 1:1 into the intervention group and the control group. Participants in the control group will receive a health education booklet introducing voluntary medical male circumcision. In addition to the health education booklet received by the control group, … |
ZIXIN WANG; | 2017-01-01 |
| 98 | Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer’s Disease When Treated With Valaciclovir – Open Fas II Pilot Study (VALZ-Pilot) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer’s disease or Mild Cognitive Impairment of Alzheimer’s Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of Valaciclovir treatment. Participants will be investigated using different measures before and after the treatment period. |
HUGO LOVHEIM; | 2016-12-01 |
| 99 | Observation on Effect of Anti–inflammatory and Inhibition of Recurrence on The Herpes Simplex Keratitis After Topical NSAIDs Administration PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: As is reported, NSAIDs(pranoprofen ,bromfenac) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs. To explore more effective clinical treatment of viral keratitis patients to control the inflammatory damage, save the visual function and reduce the recurrence of the virus ,we observe the effect of anti-inflammatory and inhibition of recurrence on the herpes simplex virus after topical NSAIDs administration. |
YANG JIANG; | 2016-11-01 |
| 100 | A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection. |
GENOCEA BIOSCIENCES | 2016-09-16 |
| 101 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate The Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes). |
VICAL | 2016-09-01 |
| 102 | A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. |
NAOTO T UENO; | 2016-08-01 |
| 103 | Phase I Clinical Trial of HSV G207 Alone or With A Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication and tumor cell killing, will also be tested. |
GREGORY K. FRIEDMAN; | 2016-05-01 |
| 104 | Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) Standard Injection in Tumor Treatment Scheme Failed M1c Ⅳ Period Malignant Melanoma Spread to The Liver Open I-c Phase of Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Recombinant human GM-CSF herpes simplex virus injection (OrienX010) is a genetically engineered from Chinese patients oral separation of wild type 1 herpes simplex virus (HSV) as the carrier insert GM-CSF gene therapy drug.After gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human gm-csf gene.The drug after tumor site local injections of dosing, on the one hand, because of the soluble tumor characteristics of herpes simplex virus, … |
ORIENGENE BIOTECHNOLOGY | 2016-03-29 |
| 105 | A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving The Central Nervous System (CNS Disease) Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to identify if a Novel Antiviral Drug could be used to treat babies with Herpes Simplex Virus (HSV) with central nervous system (CNS) disease. In this study the investigators will identify the best dose for young children as well as identify additional safety information about the Novel Antiviral Drug. |
DAVID KIMBERLIN; | 2016-01-01 |
| 106 | Effects of Melatonin in The Treatment of Genital Herpes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Genital herpes is a common and increasingly-common infection worldwide. The annual incidence in the United States is 1.75 per 1000 inhabitants. The etiologic agent is the herpes type 1 and 2 strains simplex virus. Classical Treatment is with acyclovir which decreases the duration of the disease and prevents rashes but has no curative effect. Also, studies show herpes resistance to acyclovir which has stimulating research into new drugs to treat this condition. Authors suggest melatonin way be a therapeutic agent in herpetic disease due to its modulatory action in immune and inflammatory responses when administered in adequate doses. Therefore, … |
UNIVERSITY OF SAO PAULO GENERAL HOSPITAL | 2015-09-02 |
| 107 | A Prospective, Randomized Trial of Antiviral Prophylaxis in A Population of Burn Patients Related Papers Related Patents Related Grants Related Experts View Highlight: A prospective, randomized trial to calculate incidence of Herpes Simplex Virus in an in-patient burn population and determine efficacy of prophylactic antiviral therapy to prevent viral infection and/or reactivation. Hypothesis is that antiviral prophylaxis will be effective in reducing HSV infection/reactivation. |
MICHAEL W NEUMEISTER; | 2015-09-01 |
| 108 | Evidence Linking The Role of Viruses, Bacteria and Placental MIR155 in Chronic Periodontitis and Preeclampsia- A Genetic Microbiological Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Preeclamptic women with and without chronic periodontitis were recruited for the study. Subgingival plaque samples and placental tissue samples(postpartum) were obtained from the participants for the microbial analysis(bacteria, viruses) and MIR155 levels and comparison was done among groups. this study was designed in order to evaluate the role of periodontal microorganisms in preeclampsia and to find compare the MIR155 levels among participants, so as to check its importance as a biomarker for inflammatory disease like preeclampsia. |
JAIDEEP MAHENDRA; | 2015-08-01 |
| 109 | Human Herpes Viruses in Burn Victims: A Systematic Review PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: Herpes simplex virus, cytomegalovirus and varicella zoster virus infection are purported to play a pivotal role in morbidity and mortality in burns. Thus far, there is no existing systematic review (Level of Evidence III or higher) describing the unique role as well as concurrent infections of these viruses in burns. The aim of this review is to point out the clinical differences between these human herpes virus subtypes, to outline established therapy approaches, and to provide evidence for virus related morbidity and mortality in burns. |
THE UNIVERSITY OF TEXAS MEDICAL BRANCH GALVESTON | 2015-03-01 |
| 110 | An Assessment of An HIV Prevention Intervention (Project AIM) on Youth Sexual Intentions, Sexual Behaviors and HSV-2 Incidence and Prevalence in Junior Secondary Schools in Eastern Botswana PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to examine the effectiveness of an HIV prevention intervention called Project AIM (Adult Identity Mentoring) to delay onset of sexual activity and reduce sexual risk behaviors among students (approximate ages 12- 17 years) in junior secondary schools (Form 1 – 3) in Eastern Botswana. |
KIM S MILLER; | 2014-08-01 |
| 111 | Prospective Study of The Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The main objective of this study is: – to establish etiology of acute aseptic meningitis/meningoencephalitis in Slovenia – to assess the clinical course and outcome of tick-borne encephalitis and Lyme neuroborreliosis – to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with tick-borne encephalitis and Lyme neuroborreliosis |
FRANC STRLE; | 2014-06-01 |
| 112 | Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age. Women with symptomatic BV may present with malodorous discharge that is off-white, thin, and homogenous and has a fishy smell especially after intercourse. It is of importance to treat women with BV, as this condition is associated with serious risks, such as an increased risk of preterm birth in pregnant women, … |
UNIVERSITY HOSPITAL INSELSPITAL BERNE | 2014-06-01 |
| 113 | Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson’s Disease Related Papers Related Patents Related Grants Related Experts View Highlight: Implantation of Celavie human stem cells (OK99) is intended to address the underlying pathology of the disease by replacing damaged/destroyed cells of the brain, and/or stimulating the patient’s brain to repair itself. |
IGNACIO MADRAZO; | 2014-05-01 |
| 114 | Efficacy of A Preemptive Treatment By Ganciclovir or By Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting A Viral Replication (CMV And/or HSV) – Prospective, Randomized, Double-blinded Multicenter Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to show that a preemptive treatment by ganciclovir (for positive CMV viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the number of ventilator-free days at Day 60. |
LAURENT PAPAZIAN; | 2014-03-01 |
| 115 | Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Morbidity and mortality of ICU patients is increased by the development of a immunosuppression systemic (IS). This IS develops in the early hours of hospitalization and is responsible for severe infections, including viral reactivations (Cytomegalovirus or Herpes Simplex Virus). Viral reactivation was associated with increased morbidity and mortality in intensive care units. In clinical practice, they are searched at the onset of organ failure or unexplained fever. The investigators wish to conduct this research in the stroke patients to assess the predictive power of these viral reactivations on the duration of mechanical ventilation. |
KARIM ASEHNOUNE; | 2014-01-05 |
| 116 | Device Trial: Identification of Herpes Simplex Virus (HSV) Shedding in The Female Genital Tract of Pregnant and Nonpregnant Women By GeneXpert PCR, Routine PCR, and Culture PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: PCR detection of HSV DNA shedding in the female genital tract using the GeneXpert system (Cepheid, Sunnyvale CA) will be compared with traditional (routine) PCR (pregnant and nonpregnant women) and with HSV culture (nonpregnant women). The GeneXpert system performs all sample-processing steps and real-time PCR in a single integrated cartridge. The standard cartridge is an inexpensive disposable plastic cartridge with filtration and ultrasonic lysis capabilities. It consists chiefly of several combined molded plastic components: a cartridge body containing eleven fluid reservoirs or chambers along with an attached PCR tube, … |
DAVID KIMBERLIN; | 2014-01-01 |
| 117 | A Two Arm, Multi-Site Clinical Evaluation of The ARIES HSV 1&2 Assay in Symptomatic Patients PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The ARIES HSV 1&2 Assay is a PCR based test for the direct detection and typing of herpes simplex virus (HSV 1 & 2) DNA. The objective is to establish the diagnostic accuracy of ARIES HSV-1&2 Assay. |
LUMINEX | 2014-01-01 |
| 118 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate The Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2). |
VICAL | 2013-12-01 |
| 119 | A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG) Related Papers Related Patents Related Grants Related Experts View Highlight: This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery. HSV1716 is a virus that has a gene which has been changed or removed (mutated) in such a way that lets the virus multiply in dividing cells of the tumor and kills the tumor cells. |
MARIKO DEWIRE; | 2013-12-01 |
| 120 | A Phase 1 Study of M032 (NSC 733972), A Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simples Virus-1 in patients who would benefit from surgical resection of recurrent glioma |
JAMES MARKERT; | 2013-11-25 |
| 121 | Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This prospective, randomized, single-blinded, placebo controlled trial will examine the safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring when used continuously for 14 consecutive days. The primary objective is to assess the safety of TDF vaginal rings when used continuously for 14 days by healthy, HIV-uninfected, sexually abstinent women, as compared with a placebo vaginal ring. |
MARLA KELLER; | 2013-11-19 |
| 122 | Phase II RCT of Comprehensive Triaged HIV Prevention: Tanzania PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a 3-year Phase II trial of a HIV prevention strategy designed to significantly reduce population-level HIV incidence. The study design is a two-arm community randomized controlled trial of Comprehensive Triaged HIV Prevention (CTHP) which includes: (a) Access to an HIV center which will provide free HIV testing and counseling, (b) Educational activities related to HIV risk behavior, (c) Special counseling sessions for HIV-infected clients, (d) A onetime provision of a small amount of food or health products for sex partners of persons testing positive for HIV or reporting HIV risk behaviors when they come to receive HIV testing, … |
MICHAEL D SWEAT; | 2013-10-01 |
| 123 | Comparison Between The Sensibility of The Flocked Swab and The Traditional Fiber Swab for The Diagnosis of The Herpes Simplex Epithelial Keratitis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to compare a corneal sampling realized by a flocked swab (flocked swab regular 519CS01) with a sampling by traditional fiber swab (Copan regular swab 164KS01 in polyester). Their impact on the sensibility of the viral culture in the Herpes simplex epithelial keratitis will be the primary objective of this study. |
PATRICIA-ANN LAUGHREA; | 2013-10-01 |
| 124 | Phase I Study of The Safety of A Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: – Herpes simplex virus type 2 (HSV-2) is a major cause of genital herpes. It can also cause serious infection in newborns and in people with weakened immune systems. It increases the risk of getting an HIV infection and of spreading HIV to someone else. Therefore, a vaccine that could prevent genital herpes could improve the general health of the world s population. Researchers want to study whether a new vaccine, HSV529, which may be used in the future to prevent herpes infections, is safe. Objectives: – To test whether a new herpes vaccine is safe. Eligibility: – … |
JEFFREY I COHEN; | 2013-09-26 |
| 125 | Phase III Study of ASP2151 in Herpes Simplex Patients – A Double-blind, Placebo-controlled Study – PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex. |
MARUHO | 2013-08-01 |
| 126 | A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate The Efficacy, Safety and Tolerability of A Polyethylene Glycol-formulation and The Viral Shedding in Patients Suffering From Genital Herpes Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is therefore to investigate the efficacy of the PEG-formulation to reduce the frequency and duration of genital herpes recurrences, to assess its safety and tolerability and to investigate its effect on shedding. |
THOMAS KUENDIG; | 2013-02-01 |
| 127 | DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The objective of this study is to screen treated Trichomonas vaginalis (TV) positive women weekly using culture and Polymerase Chain Reaction (PCR) to determine how long TV DNA is detectable post treatment and to examine potential confounders to clearance such as bacterial vaginosis. |
PATRICIA KISSINGER; | 2012-11-01 |
| 128 | A Phase 2a, Multicenter, Double-blinded, Randomized, 2-Period Trial to Evaluate The Effect of HerpV Administered in Combination With The Stimulon® Adjuvant QS-21 on Viral Shedding in Adults With Recurrent Genital Herpes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment. |
AGENUS | 2012-10-29 |
| 129 | A Phase I/IIa Study of The Safety, Tolerability and Biological Effect of Single and Repeat Administration of The Selectively Replication-competent Herpes Simplex Virus HSV1716 Into The Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5. Malignant mesothelioma is an aggressive, asbestos-related tumour of the pleural and peritoneal cavities. It is a rare cancer which occurs in individuals who have been exposed to asbestos, although it typically occurs decades after exposure (10-40 years later). Malignant pleural mesothelioma forms plaques that are distributed on the surface of the pleural space in the lung. Approximately 30% of patients require an indwelling pleural catheter for drainage of pleural effusions. In this patient group, … |
PENELLA J WOLL; | 2012-10-01 |
| 130 | A Prospective, Randomized, Multicenter Study of The Efficacy and Safety of Famciclovir 125 Mg Comparing to Aciclovir 200 Mg in Patients With Active Recurrent Genital Herpes PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as famciclovir and aciclovir. This is a phase III, multicenter, randomized, parallel-group study to compare the efficacy and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with active recurrent genital herpes. |
EMS | 2012-07-01 |
| 131 | A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate the preventive efficacy for HSV infection and safety of valaciclovir (VACV) in the adult and pediatric HSCT patients. |
GLAXOSMITHKLINE | 2012-05-07 |
| 132 | A Phase I Study of Recombinant HGM-CSF Herpes Simplex Virus PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer. |
JIN LI; | 2012-05-01 |
| 133 | Safety, Efficacy, and Patient Satisfaction of Cervical Ripening With Transcervical Use of The Foley Catheter in An Outpatient Setting PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This study examines whether outpatient pre-induction cervical ripening improves patient satisfaction and is safe and effective. |
GREGORY W. LAU; | 2012-04-01 |
| 134 | HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to examine the effects of valacyclovir in patients who have chronic hepatitis C, antibodies to herpes simplex type 1 infection but do not have antibodies to herpes simplex type 2 infection. Herpes simplex type 1 infection commonly causes cold sores or fever blisters, also known as herpes labialis, … |
MARY J BURTON; | 2012-04-01 |
| 135 | A Pilot Study Using High Dose Busulfan and Bortezomib As Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients Related Papers Related Patents Related Grants Related Experts View Highlight: This pilot phase II trial studies how well giving high dose busulfan together with bortezomib works in treating patients with high risk multiple myeloma undergoing stem cell transplant. Drugs used in chemotherapy, such as busulfan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cells growth. Giving busulfan together with bortezomib before a stem cell transplant may kill more cancer cells |
ZAID AL-KADHIMI; | 2012-02-01 |
| 136 | Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to study the effects of valacyclovir on patients who have hepatitis C and antibodies to herpes simplex type-2. Herpes simplex type 2 is a virus which causes genital herpes. Some persons with genital herpes have sores in their private areas but most persons do not have any symptoms at all. Valacyclovir is a medication which is commonly used to treat or prevent outbreaks of genital herpes. This medication is already approved by the Food and Drug Administration to treat genital herpes. Valacyclovir has not been approved to treat chronic hepatitis C. The study will take 16 weeks. Participants will be assigned to take either the study drug, valacyclovir, or a sugar pill that looks exactly like valacyclovir. The researchers and the persons participating will not know which medication they are receiving. Study visits will occur every two weeks and will take approximately 3-45 minutes. All study visits will occur at the G.V. Sonny Montgomery VA Medical Center. |
MARY J BURTON; | 2011-11-01 |
| 137 | A Phase III, Multi-Centre, Randomized Controlled Trial to Assess The Safety and Effectiveness of The Vaginal Microbicide 1% Tenofovir Gel in The Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of The Microbicide on The Incidence of Herpes Simplex Virus Type 2 Infection PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women. |
CONRAD | 2011-10-01 |
| 138 | Sexually Transmitted Infections Among African American Women Who Have Sex With Women PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine rates of sexually transmitted infections (STIs) among African American women who have sex with women (AAWSW). In addition, the study is interested in better understanding the types of risk behaviors that place AAWSW at risk for STIs. The investigators hypothesis is that AAWSW experience high rates of STIs, similar to heterosexual African American women. Knowledge gained from this study will guide development of interventions to reduce women’s risk for these types of infections and will improve how AAWSW are screened for STIs. |
CHRISTINA MUZNY; | 2011-08-01 |
| 139 | Therapeutic Safety and Efficacy of REP 2139 (REP 9AC’) in HBV Infected Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infection. REP 2055 has been shown to have potent therapeutic effect against established DHBV infection in vivo REP 2055 was additionally shown to have significant antiviral effects in patients with chronic HBV infection in the previous REP 101 study. REP 2139 is a version of REP 2055 designed for improved administration tolerability and stability. The safety and antiviral activity REP 2139, … |
MAMUN AL-MAHTAB; | 2011-08-01 |
| 140 | A Case Control Study of Women With Multiple Sexual Partners Attending The Jefferson County Department of Health Sexually Transmitted Diseases Clinic PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Both population based surveys and more focused research studies indicate that increased numbers of sexual partners and partner concurrency contribute to increased risk for acquisition of sexually transmitted infection (STI), including HIV infection. However, unlike for men, both national and sub-population-based studies consistently find that the great majority of women with or without STIs report only 1-2 sex partners in the preceding year and that a minority of women acknowledge > 3 sex partners over the same period, … |
CHRISTINA MUZNY; | 2011-05-01 |
| 141 | Prospective Evaluation of The Impact of Bacterial Vaginosis and Its Treatment on Mucosal Susceptibility to HIV-1 Infection and Endpoints of Cervico-Vaginal Safety PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a research study to determine whether bacterial vaginosis (BV) changes the cervico-vaginal tissue (skin covering the cervix and vagina) and makes women at higher risk for getting HIV (Human Immunodeficiency Virus). Vaginal and cervical tissue biopsies from women with BV will be obtained and infected OUTSIDE the body (ex vivo) with HIV. BV is a vaginal infection that develops when there is an imbalance in the normal bacteria found in a woman’s vagina. It is the most common cause of vaginal discharge among women of child-bearing age. BV infections potentially harm the safety of the tissue surrounding the cervico-vaginal region. When the cervico-vaginal tissue is not well protected, the risk of acquiring HIV from an infected partner might increase significantly. Studies have shown that HIV is more common in women with BV than in women with normal vaginal bacteria. Treatment of BV typically involves the use of antibiotics. Antibiotics kill harmful bacteria and provide a temporary relief from the symptoms caused by the infection. Women participating in this study will use the generic antibiotic metronidazole, also known as Flagyl. The Center for Disease Control and Prevention (CDC) recommends Flagyl for the treatment of BV. The study will evaluate HIV infection and safety of cervico-vaginal tissue in women at 3 different time periods: 1. During a BV infection 2. Approximately 1 week after completing a 7-day course of metronidazole therapy 3. Approximately 1 month after completing the 7-day course of metronidazole therapy You will not come in contact with HIV during this study – only your samples (after we have removed them from your vagina/cervix) come in contact with HIV. |
ANNIE THURMAN; | 2011-04-01 |
| 142 | Effects of Cash Transfer for The Prevention of HIV in Young South African Women PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Cash transfers to young women for staying in school and its effect on acquiring HIV |
XAVIER GOMEZ-OLIVE; | 2011-03-01 |
| 143 | A Pilot Study to Introduce Male Circumcision (MC) Services to Prevent HIV Infection in Two High Prevalence Areas of The Dominican Republic (DR) PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine the feasibility of introducing voluntary medical male circumcision as a form of HIV prevention in high HIV prevalence areas in the Dominican Republic. |
MAXIMO BRITO; | 2011-02-01 |
| 144 | A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By Double-stranded DNA Viruses PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es). Subjects received either a weight-based or a fixed dose of oral BCV once weekly (QW) or twice weekly (BIW) for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA by polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer. Under the first protocol amendment, … |
CHIMERIX | 2010-12-01 |
| 145 | VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to compare the levels of immune and inflammatory markers among HIV-1, HSV-2 co-infected adults achieving plasma HIV RNA suppression to <50 copies/mL, between those randomized to valacyclovir and placebo, over a twelve-week intervention period. |
DARRELL HS TAN; | 2010-09-01 |
| 146 | A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab As Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Related Papers Related Patents Related Grants Related Experts View Highlight: This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor. Therefore It will test the efficacy of combining sirolimus, tacrolimus, antithymocyte globulin, and rituximab in preventing graft versus host disease in transplants from HLA Haploidentical and partially mismatched donors. |
ZAID AL-KADHIMI; | 2010-08-01 |
| 147 | Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for The Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background. Mucositis is a complication of chemotherapy with no effective treatment. Aim.To evaluate the efficacy of sub-microbial doses of doxycycline hyclate in preventing the development of oral mucositis in patients with acute leukemia (AL) treated with induction chemotherapy. Hypothesis. Doxycycline hyclate administration in sub-microbial dosage will reduce the incidence of oral mucositis in patients with AL who receive induction chemotherapy. Methods. Double-blind, randomized, placebo-controlled clinical trial. At the Cancer National Institute (INCan), adult patients (> 18 years of age) with acute leukemia of recent diagnosis, … |
JUAN R LABARDINI-MENDEZ; | 2010-05-01 |
| 148 | Examining The Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in The Cervix PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman’s risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HIV target cells (CD4 T cells and dendritic cells) in the cervical mucosa. However, recent clinical trials showed no impact of HSV2 suppression on HIV acquisition rates. The reasons for this negative result are unclear. The investigators propose to examine the effect of valacyclovir (a widely used herpes medication) treatment on cervical immunology and HIV target cells in the cervix. The study will take the form of a randomized, … |
RUPERT KAUL; | 2010-04-01 |
| 149 | VALacyclovir In Delaying Antiretroviral Treatment Entry PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is a multicentre, randomized, placebo-controlled, fully blinded, clinical trial of twice daily oral valacyclovir 500mg versus placebo with the goal of delaying the need for initiating HAART among HIV infected individuals who neither use nor require HAART, and who have not used chronic suppressive anti-HSV therapy for at least the 6 months prior to study initiation. |
SHARON L WALMSLEY; | 2010-03-01 |
| 150 | A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Patients with relapsed solid tumors such as sarcomas and neuroblastoma have a poor survival, generally < 20%. There is an urgent need for new treatments that are safe and effective. HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5, a specific determinant of virulence. Mutants lacking the RL1 gene are capable of replication in actively dividing cells but not in terminally differentiated cells - a phenotype exploited to selectively kill tumor cells. In previous clinical studies, ... |
TIMOTHY CRIPE; | 2010-03-01 |
| 151 | An Open-label Trial of The Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to look at the effect of daily herpes medication, valacyclovir, on HIV levels in the blood in persons who are HIV positive and do not have oral or genital herpes. |
ANNA WALD; | 2010-01-01 |
| 152 | The Natural History of Severe Viral Infections and Characterization of Immune Defects PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: * Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive state. However, some people may become quite ill when they are infected with a particular virus, … |
JESSICA R DURKEE-SHOCK; | 2009-10-01 |
| 153 | Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous And/or Superficial Lesions PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions. |
ROBERT L FERRIS; | 2009-08-01 |
| 154 | Serologic Assays for The Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purposes of this study are: – To determine the accuracy of commercially available serologic assays in diagnosing patients with herpes simplex virus type 2 (HSV-2); – To assess the sensitivity and specificity of the commerical assays using HSV-2 western blot as the gold standard in a diverse patient population; – To develop testing strategies and recommendations for screening asymptomatic populations for HSV-2. |
DONNA FELSENSTEIN; | 2009-07-01 |
| 155 | A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: – A cold sore is usually a blistering rash on or near the lips, caused by infection with herpes simplex virus. After the first infection, the virus goes into a dormant (inactive) state, but it can continue to cause cold sores. – Most people with the herpes simplex virus have a few episodes of cold sores per year. However, some individuals may have many recurrent episodes that are uncomfortable and may cause embarrassment. Researchers are attempting to find treatments that can decrease the number of cold sore episodes for people who have six or more episodes per year. – … |
JEFFREY COHEN; | 2009-06-01 |
| 156 | Prevalence of Asymptomatic and Symptomatic Infection of N. Gonorrheae and C. Trachomatis and Seroprevalence of HSV Typ 2 and Sexual Health Seeking Behaviour in People With HIV Infection in Bern PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: There has been an increase in incidence in sexually transmitted infections in HIV infected patients in the last years. In this study the investigators will prospectively evaluate the prevalence of symptomatic and asymptomatic infections with N. gonorrhea and Ch. trachomatis as well as the seroprevalence of Herpes simplex Type 2 infection in HIV-infected patients attending the clinic for infectious diseases at the Berne University Hospital. In addition, participants will be asked to fill out a questionnaire on sexual behaviour and sexual health. Study hypothesis: STI prevalence is high in certain risk-groups to justify screening in regular intervals. |
HANSJAKOB FURRER; | 2009-05-01 |
| 157 | Valacyclovir Suppression to Improve The Stability of Vaginal Flora Among HSV-2 Seropositive Women Related Papers Related Patents Related Grants Related Experts View Highlight: We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2. We have preliminary data that suggests the presence of HSV-2 increases the risk for Group B Streptococcus colonization as well as many other deleterious organisms (e.g. Streptococcus pseudoporcinus), in addition to increasing the risk for acquisition of BV-associated vaginal flora. We will be examining the effects of suppressive therapy on the vaginal flora of any HSV-2 seropositive woman. |
THOMAS L. CHERPES; | 2009-02-01 |
| 158 | Seroprevalence of HSV-2 in HIV Infected Subjects and The Effect of Daiy Valacyclovir in The Reduction of HSV-2 Recurrences and Viral Shedding PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily secretions. |
NICHOLAS VAN WAGONER; | 2009-01-01 |
| 159 | Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a prospective study to evaluate the pharmacokinetics, clinical and virologic response to acyclovir episodic therapy for genital herpes ulcers in HIV negative African women. |
STEWART REID; | 2009-01-01 |
| 160 | Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To examine the time to healing of genital lesion and duration of herpes simplex virus (HSV) shedding from genetic ulcer disease (GUD) among 90 HIV-negative African women who have a history of GUD and are HSV-2 seropositive and HIV-1 seronegative randomized in a 2:1 ratio to receive episodic acyclovir 400mg orally three times daily or matching placebo three times daily for 5 days and who are followed for a total of 13 days. |
CONNIE CELUM; | 2009-01-01 |
| 161 | Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients Related Papers Related Patents Related Grants Related Experts View Highlight: REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry activity against hepatitis C virus and entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infection. REP 2055 has been shown to have potent prophylactic effect against HCV infection in vivo and potent therapeutic effect against established DHBV infection in vivo The REP 101 protocol is the first-in-man proof of concept study designed to investigate the safety and antiviral activity of REP 2055 administration in human patients with chronic HBV or HCV infection. |
MAMUN AL-MAHTAB; | 2009-01-01 |
| 162 | Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in The Neutropenic Patient PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in patients with neutropenia. PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is comparing two doses of acyclovir in preventing herpes simplex virus infection in patients with neutropenia. |
M. JAY BROWN; | 2008-11-01 |
| 163 | A Randomized, Cross-Over Study to Evaluate The Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record. Please refer to the History of Changes on posting NCT00362297 for a detailed summary of the modifications. The purpose of the research study is to evaluate the effectiveness of high-dose valacyclovir compared to once daily valacyclovir for reduction of asymptomatic HSV-2 genital shedding in persons with genital herpes. The study will enroll men and women who are 18 years or older, … |
CHRISTINE JOHNSTON; | 2008-11-01 |
| 164 | A Randomized, Cross-Over Study to Evaluate The Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no medication to better define the effect of acyclovir on short bursts of rapidly cleared HSV-2 shedding. This study will be a randomized, open label, cross-over trial. We hypothesize that short bursts of HSV-2 reactivation will not be suppressed by acyclovir. |
CHRISTINE JOHNSTON; | 2008-08-01 |
| 165 | Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison and Set Up The Notional Halfway Home in Union Area of Medical Facility PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: It is difficult to detect the intestinal protozoal infections among the HIV-infected persons or travelers diarrhea by using the traditional microscopy or staining methods. The purpose of this study aimed at finding out the appropriate diagnostic methods and the infection rate of the intestinal protozoa, including the Entamoeba, Cryptosporidium and Giardia among the HIV-infected persons by using the antigen detection method and biological method. The investigators also tried to analyze the associated HIV infection status and sexual transmitted diseases (STD) including Gonorrhea, Chlamydial trachomatis, Syphilis, Genital warts and Herpes simplex virus in this study. The study will collect the blood, … |
KAOHSIUNG MEDICAL UNIVERSITY CHUNG HO MEMORIAL HOSPITAL | 2008-04-01 |
| 166 | Infectious Causes of Uveitis, With Special Focus on Infection With Leptospira PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Uveitis is an inflammatory disease of one or both eyes. Uveitis will in severe cases lead to permanent loss of vision/blindness on the affected eye. Uveitis can be caused by autoimmune disease, infections and rarely trauma, but 50 % of the cases remain of unknown origin. Intraocular infections are from previous studies, … |
STEEN VILLUMSEN; | 2008-04-01 |
| 167 | A Single Center, Open Label, Longitudinal Single Arm Study to Compare The Efficacy and Safety of Prophylactic Famciclovir 500 Mg B.d. in HIV Positive Adults With Recurrent Genital Herpes PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To determine the efficacy of Famvir 500mg bd as suppressive antiviral therapy for acute genital Herpes simplex virus (HSV) outbreaks in HIV subjects. |
MARK BLOCH; | 2008-03-01 |
| 168 | Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine The Maximum Tolerable Dose of A Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary purpose of this study is to examine the safety of NP2 (a nonreplicating HSV-based vector expressing enkephalin) in patients with cancer pain. The secondary purpose is to evaluate efficacy. |
DAVID J FINK; | 2008-02-01 |
| 169 | A Research Study Examining The Effectiveness of Distant Activation of ACE Pigments Associated With Recurrent Human Herpes Simplex Virus-Induced Skin Lesions PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The research question to be addressed is whether indirect phototherapy based activation of the body’s alternative cellular energy (ACE) pathway will lead to expedited healing of active herpes simplex virus (HSV) and herpes zoster virus (HZV)skin lesions, and also possibly inhibit both latent HSV infections and residual HZV infections. |
W JOHN MARTIN; | 2008-01-01 |
| 170 | Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma. |
DING MA; | 2008-01-01 |
| 171 | Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners. |
ANNA WALD; | 2008-01-01 |
| 172 | Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV. |
THOMAS L CHERPES; | 2007-12-01 |
| 173 | Efficacy of Lazolex® Gel in The Treatment of Herpes Simplex Mucocutaneous Infections and The Prevention of Recurrences: A Pilot Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Study aimed to evaluate the efficacy and tolerance of Lazolex®, an emollient gel, to treat mucocutaneous lesions caused by herpes simplex virus. |
TINA A. KITUASHVILI; | 2007-11-27 |
| 174 | A Multicenter, Open-label, Single-arm Study to Evaluate The Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection |
JEFFERY L. BLUMER; | 2007-10-01 |
| 175 | A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: A study of ASP2151 in subjects with recurrent outbreaks of genital herpes. |
ASTELLAS PHARMA | 2007-06-21 |
| 176 | A Randomized, Multicenter, Double-blind Study to Compare The Efficacy of Single-day Treatment (1000 Mg B.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes |
DALU MOHAMMED; | 2007-06-01 |
| 177 | A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus that causes commonly occurring and recurrent cold sores. |
KONASALE PRASAD; | 2007-06-01 |
| 178 | Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to evaluate the pattern of viral shedding after beginning treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with the pattern of viral shedding during an untreated clinical recurrence of genital herpes. |
ANNA WALD; | 2007-06-01 |
| 179 | Phase IIb Trial to Assess The Safety and Effectiveness of The Vaginal Microbicide 1% Tenofovir Gel for The Prevention of HIV Infection in Women in South Africa PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase IIb, two-arm, double-blinded, randomised, placebo controlled trial comparing 1% Tenofovir gel with a placebo gel is an expanded safety and effectiveness trial involving 900 young women at risk of sexually transmitted HIV infection. Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study gel within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. All participants will receive HIV risk reduction counselling, condoms, … |
SALIM S ABDOOL KARIM; | 2007-05-01 |
| 180 | A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a sixteen week, randomized, double-blind add-on study of valacyclovir versus placebo in approximately 60 outpatients meeting diagnostic criteria according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV Bipolar I or II disorder, … |
JENNIFER L PAYNE; | 2007-03-01 |
| 181 | Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The usefulness of diagnostic vitrectomy in patients with suspected sarcoidosis with posterior segment involvement (in whom a diagnosis cannot be determined by conventional methods) has not been well described. We hypothesized that diagnostic vitrectomy would help establish the diagnosis in these challenging cases. Herein, we evaluated the diagnostic yield of vitreous biopsy in patients with suspected sarcoidosis-associated uveitis that affected the posterior segment.This is a retrospective interventional case series. Cases of intermediate, posterior or panuveitis that could not be characterized by clinical examination, ancillary, … |
GLENN J JAFFE; | 2007-01-01 |
| 182 | An Expanded Phase I Randomized Placebo Controlled Trial of The Safety and Tolerability of 3 Percent W/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to test the safety and tolerability of a medication applied vaginally twice daily in females versus placebo (inactive substance). Study participants will include 60 women, ages 18-24, non-pregnant, previously sexually active, Human Immunodeficiency Virus (HIV) negative and sexually transmitted infection (STI) free, in San Francisco or Kisuma, Kenya. Each study participant will be followed for 14 days of product use and an additional 7 days for safety assessments. Study procedures will include a physical exam with a pap smear, urine testing, blood sample testing, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2006-12-01 |
| 183 | A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2 (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and HSV-2 infections. HSV-2 increases the amount of HIV virus in the blood of infected people and may make HIV progress faster. The study will evaluate: Whether people who take acyclovir can avoid antiretroviral treatment until later in their lives Whether people who take acyclovir get fewer genital ulcers How well people are able to take acyclovir and any side effects they experience from it Differences in the amount of HIV virus in the blood of patients who are and are not taking acyclovir, and how HIV/AIDS is different in these patients. People 18 years of age and older living in the Rakai district of Uganda who are infected with both HIV (early stage disease) and HSV-2 may be eligible for this study. Participants are randomly assigned to take the study drug, acyclovir, or a placebo (look-alike pill with no active ingredient) daily for 2 years. During this time, they visit the clinic once a month for a routine physical examination. Patients who develop genital ulcers or complications of HIV are treated for the problem, and patients whose HIV disease progresses, requiring them to begin antiretroviral therapy, are treated accordingly. |
STEVEN REYNOLDS; | 2006-11-01 |
| 184 | A Randomized, Cross-Over Study to Evaluate The Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the research study is to evaluate the effectiveness of high-dose acyclovir compared to valacyclovir for reduction of asymptomatic genital shedding in persons with genital herpes. The study will enroll men and women who are 18 years or older, … |
CHRISTINE JOHNSTON; | 2006-09-01 |
| 185 | A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for The Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether acyclovir is effective in suppressing HIV viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are starting HIV treatment for the first time. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2006-09-01 |
| 186 | A Phase I Study Assessing Safety and Tolerability of A DNA Vaccine With A DNA Encoded Immunostimulator , Administered By Particle Mediated Epidermal Delivery Using The PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects’ wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body. |
STEVEN KOMJATHY; | 2006-04-01 |
| 187 | A 30-Day Double-Masked Study to Determine The Effect of Oral Valacyclovir or Oral Valacyclovir Plus Aspirin on The Shedding of Herpes Simplex Virus DNA in The Tears and Saliva of Volunteers Without Clinical Signs of Ocular Herpetic Disease PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether oral Valtrex alone or in combination with aspirin will reduce the shedding of herpes simplex virus DNA in the tears and saliva from volunteers with no evidence of ocular herpes infection. The secretion of virus into the tears and saliva might make people more susceptible to virus infection in the future if their immune system becomes deficient. The study will also try to determine if there is a correlation between shedding of viral DNA and herpes virus antibodies in serum and to determine if subjects are carriers of a special form of a gene in their blood cells, the presence of which may suggest the possibility of an increased susceptability to herpes and to Alzheimer’s disease and heart disease. |
HERBERT E KAUFMAN; | 2006-04-01 |
| 188 | A Multicenter, Randomized, Double-blind Study to Compare The Efficacy and Safety of Patient-initiated Famciclovir 1000 Mg B.i.d. X 1 Day to Valacyclovir 500 Mg B.i.d. X 3 Days in Immunocompetent Adults With Recurrent Genital Herpes PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d). |
NOVARTIS PHARMACEUTICALS | 2006-03-01 |
| 189 | Risk Factors in Atopic Dermatitis for The Development of Eczema Herpeticum PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema. Eczema herpeticum (EH) is a type of eczema that spreads due to an underlying herpes virus infection. The purpose of this research study is to identify the risk factors that may cause EH. |
THOMAS BIEBER; | 2006-03-01 |
| 190 | Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed By Human Genome Array PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to assess the immunological status of patients using Premarin. Premarin use is associated with an enhanced immune status, and possibly even some anti-cancer effect. The researchers will compare the use of Premarin with those not using hormone replacement therapy (HRT) to track the effects of Premarin in reducing the risk of infection and swelling. |
GREGOR REID; | 2006-03-01 |
| 191 | The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between. |
GLAXOSMITHKLINE | 2006-02-20 |
| 192 | Implementation of A Third Generation Sentinel Surveillance Approach Among Men Who Have Sex With Men at High Risk for HIV, Type-1 Acquisition in The Andean Region PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this observational study is to estimate the number of new HIV infections and the number and variability of antiretroviral-resistant HIV strains among men who have sex with men (MSM). Participants will be recruited from four sites in Peru and one site in Ecuador. |
JORGE SANCHEZ; | 2006-01-18 |
| 193 | Antibodies Screening in Multiple Sclerosis As A Part of An International Survey in Autoimmune Diseases PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (rheumatoid arthritis [RA], undifferentiated connective tissue disorder [UCTD], Sjogren, antiphospholipid syndrome – APS, vasculitides, systemic lupus erythematosus [SLE], polymyositis, Hashimoto, multiple sclerosis, primary biliary cirrhosis [PBC], etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity). |
ANAT ACHIRON; | 2005-09-01 |
| 194 | HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Brief summary: The current management guidelines recommended by ACOG rely on history as a screening method to determine pregnant women who are at risk for transmitting herpes to their newborn. History fails completely in identifying the women most at risk of transmitting herpes to their newborn – the seronegative woman who acquires a primary infection from her partner during pregnancy. Despite recent advances, both pregnant women and newborns continue to be at risk of acquiring herpes infection. Genital herpes infections are epidemic in the United States. In the early 1990’s, … |
DAVID A BAKER; | 2005-09-01 |
| 195 | Transfer of Herpes Simplex Virus Type 2 GD Subunit Vaccine-Induced Antibodies From Mothers to Neonates Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study to look at the antibodies (proteins from the body’s infection fighting system) in the blood of babies delivered by women who are participants in the Herpevac Trial for Women, and who were vaccinated with either two or three doses of (GlaxoSmithKline) GSK candidate vaccine gD2t/alum-MPL or hepatitis A vaccine. The goal of this study is to compare the herpes or hepatitis A antibody levels of the newborns to those of their mothers, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2005-08-01 |
| 196 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for The Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy – 400 mg of acyclovir – will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2005-04-01 |
| 197 | Valacyclovir for The Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods. |
GLAXOSMITHKLINE | 2005-03-29 |
| 198 | Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine if acyclovir episodic treatment has an effect in ulcer healing and if it should be added to the syndromic management of genital ulcer disease. |
GABRIELA PAZ BAILEY; | 2005-03-01 |
| 199 | Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The University of Washington has received funding to conduct a proof-of-concept trial to assess the impact of suppression of genital herpes on HIV infectiousness. This study (the Partners in Prevention Study) will enroll HIV discordant heterosexual couples in which the HIV-infected partner is co-infected with herpes simplex virus type 2 (HSV-2) to test the efficacy of twice daily (bid) acyclovir (400 mg) given to the HIV-infected partner to prevent transmission to his/her HIV negative partner(s). This randomized, double-blind, … |
CONNIE CELUM; | 2004-11-01 |
| 200 | Efficacy of An HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days. HIV infection can worsen genital herpes. In turn, it is possible that genital herpes increases the quantity of HIV secreted at the genital level in women infected by the 2 viruses. This study is dedicated to verify this hypothesis. |
NICOLAS NAGOT; | 2004-08-01 |
| 201 | A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate The Safety, Tolerability and Immunogenicity of PPJV7630, A Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused By HSV-2 PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects’ wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body and evaluate the effect it has on herpes outbreaks |
LARRY STANBERRY; | 2004-08-01 |
| 202 | A Study to Evaluate The Effect of Famciclovir in Reducing Herpes Virus Shedding Related Papers Related Patents Related Grants Related Experts View Highlight: The study is designed to assess the efficacy and safety of famciclovir 250 mg twice a day (bid) suppressive treatment in men and women with herpes virus type 2 (HSV-2) infection, with and without a reported history of genital herpes and with or without herpes virus type 1 (HSV-1) seropositivity. |
NOVARTIS | 2004-07-01 |
| 203 | An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of The Efficacy and Safety of Valtrex 1g QD Vs. Placebo for The Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Genital herpes (GH) is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are two types of HSV, type 1 (HSV-1) and type 2 (HSV-2); both can cause GH, although the latter is much more likely to produce frequent recurrences of GH lesions. Evidence suggests that there are advantages to using suppressive vs. episodic treatment, which include increased intervals between the pain and discomfort of genital herpes recurrences. Therefore, this study will collect safety and efficacy data on suppressive therapy with valaciclovir in subjects newly diagnosed with HSV-2 genital herpes. |
GLAXOSMITHKLINE | 2004-06-21 |
| 204 | Depression and IL-6 in Epithelial Ovarian Cancer: Genetic Diathesis and Psychological Stress Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Measuring levels of interleukin-6 and depression may help doctors understand the relationship between interleukin-6 and depression. It may also help the study of cancer in the future. PURPOSE: This clinical trial is studying depression and interleukin-6 production in patients with ovarian epithelial cancer. |
LEAH Z. FITZGERALD; | 2003-12-01 |
| 205 | A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The evidence suggests that that HSV is an important cofactor in HIV transmission. The trial’s purpose is to assess the reduction in HIV shedding associated with valacyclovir for suppression of HSV-2 reactivation. This proof-of-concept, randomized, double-blind, placebo controlled crossover trial of 20 HIV/HSV-2 co-infected men, assessed the effects of daily valacyclovir on HIV-1 levels in the plasma and rectal mucosa secretions. |
CONNIE CELUM; | 2003-08-01 |
| 206 | A Study to Determine The Safety and Efficacy of Famciclovir in The Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction Related Papers Related Patents Related Grants Related Experts View Highlight: This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH. |
NOVARTIS | 2003-06-01 |
| 207 | Multicenter Randomized Controlled Trial Evaluating The Efficacy of HIV/STD Prevention Counseling and Testing in Preventing High Risk Behaviors and New Sexually Transmitted Diseases (Project RESPECT) PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The efficacy of counseling to prevent infection with the human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs) has not been definitively shown. This multi-center randomized controlled trial (Project RESPECT) sought to compare the effects of 2 interactive HIV/STD counseling interventions with didactic prevention messages typical of current practice. A total of 5758 STD clinic patients were enrolled from 5 public STD clinics (Baltimore, Md; Denver, Colo; Long Beach, Calif; Newark, NJ; and San Francisco, Calif) between July 1993 and September 1996. Eligible participants were heterosexual, … |
MARY L KAMB; | 2003-04-01 |
| 208 | A Randomized, Double-Blind, Placebo Controlled Crossover Trial Using Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV. |
ANNA WALD; | 2003-03-01 |
| 209 | A Double-Blind, Randomized, Controlled Phase III Study to Assess The Prophylactic Efficacy and Safety of GD-Alum/MPL Vaccine in The Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evaluation of herpes if it is suspected. Participants will be involved in study related procedures for up to 20 months. |
GLAXOSMITHKLINE | 2003-01-14 |
| 210 | Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States. |
NOVARTIS | 2003-01-01 |
| 211 | Phase I Clinical Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase Of Herpes Simplex Virus) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether activation of a prodrug after intratumoral gene transfer is safe in humans, and to determine dose levels for further clinical development. |
BRUNO SANGRO GOMEZ-ACEBO; | 2002-12-01 |
| 212 | Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine As A Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: 1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2. Randomization will be a stratified permuted-block design. 2.1The patients will be stratified into standard risk vs. high risk group, and related vs. unrelated donor. Standard risk group will be defined as follows: patients with acute leukemia in first remission, CML in chronic phase, … |
JE-HWAN LEE; | 2002-05-01 |
| 213 | A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation. |
FRED HUTCHINSON CANCER CENTER | 2001-01-01 |
| 214 | A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy. |
MEMORIAL SLOAN KETTERING CANCER CENTER | 2000-10-01 |
| 215 | A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204) PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study involves patients 12 years and older who have been diagnosed with herpes simplex encephalitis (HSE) by a specific laboratory test and have completed treatment or are being treated with intravenous (given through a needle inserted into a vein) acyclovir. The purpose of the study is to determine if treatment with 4 tablets, 500 milligrams each, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2000-09-01 |
| 216 | Persistence of Epstein-Barr Virus in Vivo PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will examine the effects of long-term antiviral therapy with valaciclovir (Valtrex) on Epstein-Barr virus infection. This virus infects more than 95 percent of people in the United States. Most are infected in childhood, have no symptoms, and are unaware of their infection. People infected as adolescents or adults may develop infectious mononucleosis, which usually resolves completely. Once infected, most people shed the virus from their throat occasionally, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2000-06-23 |
| 217 | Double-Blind Placebo-Controlled Study Comparing The Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for The Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS. |
SHAMAN PHARMACEUTICALS | 1999-11-02 |
| 218 | The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU. The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1999-11-02 |
| 219 | Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With The Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: To compare the safety and effectiveness of foscarnet and vidarabine treatments for AIDS patients who have herpes simplex virus infections that are resistant to standard treatment with acyclovir. Foscarnet is a drug that inhibits viruses and has been shown to be effective against infection with Cytomegalovirus and also against infection with the Herpes simplex virus in several patients with AIDS. Vidarabine has been shown to have activity against the Herpes simplex virus in patients who do not have AIDS, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1999-11-02 |
| 220 | The Pilot Study of Foscarnet Cream in The Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: PRIMARY: To evaluate the clinical activity of foscarnet cream on the index lesion of mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients previously unresponsive to acyclovir treatment. SECONDARY: To evaluate the clinical activity and virologic activity of foscarnet cream on all treated lesions in this patient population. To evaluate the local tolerance and side effects of treatment with foscarnet cream in this patient population. |
ASTRA USA | 1999-11-02 |
| 221 | The Effect of Treatment With Valacyclovir 500 Mg BID on The Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to see if valacyclovir affects the detection of HIV in genital herpes lesions in HIV-infected patients. Valacyclovir is used to treat recurrent genital herpes. |
GLAXO WELLCOME | 1999-11-02 |
| 222 | A Pilot Study to Determine The Effect of Acyclovir Treatment for Herpes Simplex Virus (HSV) Infection on Peripheral Blood HIV Viral Load PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Part A: To evaluate the impact of HSV suppression with acyclovir ( ACV ) on HIV burden in patients with asymptomatic HSV infection and at high risk for HSV reactivation. Part B: To characterize the change in plasma HIV RNA levels and other measures of HIV burden during and after a 10 day course of ACV treatment for acute HSV infection. Approximately 70% of patients infected with HIV are concurrently infected with HSV. There is new evidence to suggest that HSV may act as a co-factor in HIV disease progression. This study will attempt to determine if the upregulation of HIV RNA that occurs during symptomatic HSV reactivation also occurs during asymptomatic HSV reactivation and if suppression of HSV will result in decreased levels of HIV RNA. There is a need to determine the patterns of association between HSV and HIV. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1999-11-02 |
| 223 | A Phase I Trial to Evaluate The Pharmacokinetics, Safety, and Tolerance of Valacyclovir HCl in HIV-1 Infected Children With Herpes Simplex Infections or Varicella/Zoster Infections Related Papers Related Patents Related Grants Related Experts View Highlight: To obtain tolerance, safety, and pharmacokinetic data for oral valacyclovir hydrochloride ( 256U87 ) in HIV-1 infected children with herpes simplex virus infections ( cold sores ) and/or varicella / zoster virus infections ( chicken pox / shingles ). Varicella and zoster are common problems in HIV-infected children. It is believed that chronic oral therapy with acyclovir may result in subtherapeutic concentrations of acyclovir, resulting in resistance to that drug. Valacyclovir hydrochloride, which converts to acyclovir in the body, increases acyclovir bioavailability by 3-5 fold. |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1999-11-02 |
| 224 | A Pilot Study to Determine The Safety and Efficacy of Topically Applied SP-303T in Patients With Acquired Immunodeficiency Syndrome and Concomitant Herpes Simplex Virus (HSV) Infection Unresponsive to Acyclovir Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety and tolerance of topically applied SP-303T in AIDS patients. To observe the effect of this drug on herpes simplex virus lesions in patients who have failed to heal in response to oral or intravenous acyclovir therapy. The lack of alternative treatments for herpes simplex virus infection in patients with AIDS and the development of resistance to acyclovir for patients requiring repeated treatment presents a therapeutic dilemma for physicians. SP-303T has good in vitro activity against resistant strains and offers a convenient and inexpensive means of drug administration in comparison to the use of intravenous medication. |
SHAMAN PHARMACEUTICALS | 1999-11-02 |
| 225 | An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With The Acquired Immunodeficiency Syndrome and Other Immunodeficiencies Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV maintenance foscarnet therapy in preventing recurrent disease. To confirm the pharmacokinetics of intermittent induction and maintenance IV regimens. |
ASTRA USA | 1999-11-02 |
| 226 | An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With The Acquired Immunodeficiency Syndrome and Other Immunodeficiencies Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients. To evaluate the necessity, efficacy, and safety of IV maintenance foscarnet therapy in preventing recurrent disease. To confirm the pharmacokinetics of intermittent induction and maintenance IV regimens. |
ASTRA USA | 1999-11-02 |
| 227 | A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to The Skin, Eye, and Mouth PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to test whether long-term treatment with oral acyclovir improves the outcome for infants with herpes simplex virus (HSV) disease of the skin, eyes, and mouth (SEM). Study participants will include infants in the United States and Canada who have HSV disease of the skin, eyes, and mouth, with no central nervous system disease present. Initially, all subjects will be treated with acyclovir administered through IV access (through the vein) for 14 days while hospitalized. Participants will then be placed in one of two groups, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1999-08-01 |
| 228 | Infection and Cardiovascular Disease Related Papers Related Patents Related Grants Related Experts View Highlight: To investigate the role of chronic infection as a risk factor for vascular disease in a study of Native Americans. The primary focus is on the two most common agents Chlamydia pneumoniae and cytomegalovirus with a secondary emphasis on Helicobacter pylori. |
MICHAEL DAVIDSON; | 1999-04-01 |
| 229 | Inflammation, Infection, and Future Cardiovascular Risk Related Papers Related Patents Related Grants Related Experts View Highlight: To examine markers of underlying chronic inflammation and infection as potential risk factors for future myocardial infarction (MI), stroke (CVA), and venous thromboembolism (VTE) in plasma samples collected at baseline from healthy participants in the Physicians’ Health Study (PHS). |
PAUL RIDKER; | 1998-09-01 |
| 230 | Strategies for The Prevention of HIV Infection and The Enhancement of Reproductive Health Among Adolescents in Rural Tanzania: MEMA Kwa Vijana Trial PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: The MEMA kwa Vijana Project is a community randomised trial which aims to assess the impact of a targeted intervention on adolescent sexual and reproductive health in Mwanza Region, Tanzania. The intervention aims to reduce HIV, STD and unwanted pregnancy amongst adolescents by improving reproductive health knowledge and by teaching skills to promote sexual behaviour change, and comprises community mobilisation, skills-based education in primary schools, and youth friendly health services. The evaluation includes a detailed process evaluation, and evaluation of the impact in a cohort of approx. 10,000 adolescents who will be followed for 3 years. |
DAVID A ROSS; | 1998-07-01 |
| 231 | A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving The Central Nervous System PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to test whether long term treatment with acyclovir given orally (by mouth) improves the outcome for infants with herpes simplex virus infection of the brain or spinal cord (known as the central nervous system [CNS]). Infants with herpes viral infection of the CNS that has or has not spread to other parts of the body will be enrolled in this study. All participants will receive treatment in a hospital for 21 days with acyclovir, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1997-12-01 |
| 232 | Polymorphism of The Herpes Simplex Virus Receptor PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will examine the structure of the receptor molecule for the herpes simplex virus (HSV) and determine if the receptor’s structure is related to susceptibility to infection with the virus. There are two types of herpes virus-HSV-1 and HSV-2. HSV-1 commonly causes cold sores, and HSV-2 usually causes genital herpes. The herpes virus enters (infects) cells through protein molecules on the cell’s surface. This study will explore possible differences between the structure of the HSV receptor molecule in different people to understand better how infection occurs. The study will also look at proteins on white blood cells (Fc receptors, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1997-08-20 |
| 233 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for The Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate the effectiveness of the drug valaciclovir in preventing transmission of genital herpes from an infected to an uninfected sexual partner. Genital herpes is caused by the herpes simplex virus 2 (HSV-2), or, infrequently herpes simplex virus 1 (HSV-1). Valaciclovir prevents the herpes virus from multiplying and may also reduce its transmission between partners. Couples 18 years of age and older in which one partner is infected with HSV-2 (source partner) and the other is not (susceptible partner), … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 1997-08-01 |
| 234 | Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving The Central Nervous System PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: OBJECTIVES: I. Determine the efficacy of long term suppressive therapy with oral acyclovir in infants with herpes simplex virus infection involving the central nervous system. II. Determine whether neurologic outcome is improved in these patients when treated with this regimen. III. Determine whether continuous administration of this drug suppresses recurrent skin lesions in these patients. IV. Determine the safety of this regimen in these patients. |
NATIONAL CENTER FOR RESEARCH RESOURCES NCRR | 1997-06-01 |
| 235 | Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: OBJECTIVES: I. Determine the efficacy of long term suppressive therapy with oral acyclovir in infants with herpes simplex virus infection limited to skin, eyes, and mouth. II. Determine the neurologic outcome in these patients when treated with this regimen. III. Evaluate the significance of a positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR) result when all other CSF parameters remain normal in these patients. IV. Correlate the time to first positive CSF PCR result in the first 12 months of life with clinical neurological assessment in these patients when treated with this regimen. V. Determine whether the continuous administration of this drug suppresses recurrent skin lesions in these patients. VI. Determine the safety of this regimen in these patients. |
NATIONAL CENTER FOR RESEARCH RESOURCES NCRR | 1997-06-01 |
| 236 | Study to Evaluate The Safety of GSK Biologicals’ Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease. |
GLAXOSMITHKLINE | 1996-10-01 |
| 237 | Safety of SmithKline Beecham Biologicals’ Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to evaluate the safety of Herpes Simplex candidate vaccine (gD2t) with adjuvant and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease. |
GLAXOSMITHKLINE | 1996-03-01 |
| 238 | A PHASE I TRIAL OF HSV-TK ADENOVIRUS GENE THERAPY FOR PRIMARY BRAIN TUMORS Related Papers Related Patents Related Grants Related Experts View Highlight: RATIONALE: Inserting the gene for herpes virus into a person’s cells may improve the body’s ability to fight cancer or make the cancer more sensitive to chemotherapy using antiviral drugs such as ganciclovir. PURPOSE: Phase I trial to study the effectivenesss of gene therapy in treating patients with primary brain tumors. |
ABRAMSON CANCER CENTER OF THE UNIVERSITY OF PENNSYLVANIA | 1996-02-01 |
| 239 | Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: OBJECTIVES: I. Evaluate whether high-dose acyclovir decreases acute and long-term morbidity and mortality in neonates with central nervous system or disseminated herpes simplex virus (HSV) infection. II. Evaluate whether high-dose acyclovir is safe and tolerated in the newborn. III. Assess resistance to antiviral medication. IV. Amplify disease classification for the purpose of predicting prognosis. V. Assess any changes in viral excretion patterns. VI. Evaluate whether antigens and antibodies specific for HSV glycoproteins within the cerebrospinal fluid (CSF) predict long-term neurologic outcome. VII. Evaluate whether specific antigens and antibodies in the CSF appear late after treatment and are indicative of insidious reactivation of virus in the brain. |
NATIONAL CENTER FOR RESEARCH RESOURCES NCRR | 1995-02-01 |
| 240 | Herpetic Eye Disease Study (HEDS) II Related Papers Related Patents Related Grants Related Experts View Highlight: To determine whether early treatment (with oral acyclovir) of herpes simplex virus (HSV) ulcerations of the corneal epithelium prevents progression to the blinding complications of stromal keratitis and iridocyclitis. To determine the efficacy of low-dose oral acyclovir in preventing recurrent HSV eye infection in patients with previous episodes of herpetic eye disease. To determine the role of external factors (such as ultraviolet light or corneal trauma) and behavioral factors (such as life stress) on the induction of ocular recurrences of HSV eye infections and disease. |
NATIONAL EYE INSTITUTE NEI | 1992-10-01 |
| 241 | Gene Therapy for The Treatment of Brain Tumors Using Intra-Tumoral Transduction With The Thymidine Kinase Gene and Intravenous Ganciclovir PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Malignant brain tumors are responsible for a significant amount of deaths in children and adults. Even with advances in surgery, radiation therapy, and chemotherapy, many patients diagnosed with a malignant brain tumor survive only months to weeks. In an attempt to improve the prognosis for these patients, … |
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE NINDS | 1992-08-21 |
| 242 | Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to The Skin, Eyes, and Mouth Related Papers Related Patents Related Grants Related Experts View Highlight: OBJECTIVES: I. Determine whether acyclovir (ACV) oral suspension suppresses recurrent skin lesions and improves neurologic outcome in neonates with localized herpes simplex virus type 2 infection when administered for 6 months in a placebo-controlled study. II. Determine whether the prevention of recurrent skin lesions reduces long-term neurologic morbidity. III. Determine whether resistant disease develops after oral ACV therapy. IV. Evaluate the natural history of recurrent skin lesions. V. Measure any adverse effects and laboratory abnormalities associated with long-term oral ACV therapy in infants and young children. |
NATIONAL CENTER FOR RESEARCH RESOURCES NCRR | 1992-08-01 |
| 243 | An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate The Safety of GSK Biologicals’ Candidate GD Vaccine, With or Without 3D MPL PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of the study is to evaluate the safety and reactogenicity of candidate gD vaccine, with or without MPL, in HSV-seropositive subjects. The immune response elicited in these subjects will also be evaluated. |
GLAXOSMITHKLINE | 1992-05-01 |
| 244 | Herpetic Eye Disease Study (HEDS) I Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis in conjunction with topical trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex iridocyclitis in conjunction with treatment with topical corticosteroids and trifluridine. |
NATIONAL EYE INSTITUTE NEI | 1989-05-01 |